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One of the major mechanisms of chemical protection against carcinogenesis, mutagenesis, and
other forms of toxicity mediated by electrophiles is the induction of enzymes involved in their
metabolism, particularly phase 2 enzymes such as glutathione S-transferases (GSTs), uridine
diphosphate-glucuronosyltransferases, and NAD(P)H:quinone reductase. Furthermore, induction
of phase 2 enzymes appears to be a sufficient condition for obtaining chemoprevention and can
be achieved in many target tissues by administering any of a diverse array of naturally occurring
and synthetic chemical agents. One class of chemopreventive agents, 1,2-dithiole-3-thiones, was
developed on the basis of their potent activity in rodent tissues as inducers of GSTs. A
substituted dithiolethione, oltipraz 14-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thionel, is an effective
inhibitor of aflatoxin Bl-mediated hepatocarcinogenesis in the rat. Oltipraz produces dramatic
decreases in the levels of aflatoxin-DNA adducts in the liver as well as in the urinary levels of the
depurination product aflatoxin-N7-guanine. Corresponding increases are seen in the biliary
elimination of aflatoxin-glutathione conjugates. Administration of oltipraz results in 3- to 4-fold
increases in hepatic cytosolic GST activities and mRNA levels for some x, p and X isoforms.
Nuclear run-on assays have indicated that oltipraz treatment elevates rates of transcription of
some GST subunits. In the rat, induction of phase 2 enzymes by oltipraz is mediated, at least in
part, through the antioxidant response element in the 5' flanking region of these genes. Although
oltipraz has a very short plasma half-life, elevations in the levels of some GST isoforms can persist
up to 1 week after dosing with oltipraz. Concordantly, intermittent dosing schedules (i.e., once a
week) are nearly as effective as daily interventions for inhibition of aflatoxin-mediated hepatic
tumorigenesis. The protective efficacy of daily and weekly administration of oltipraz to people in
Qidong, People's Republic of China, who are at high risk for aflatoxin exposure and subsequent
development of hepatocellular carcinoma, is currently under evaluation. Environ Health
Perspect 105(Suppl 4):965-970 (1997)
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Introduction
There are many potential strategies for
chemical protection against the multiple
stages of carcinogenesis [see reviews by
Wattenberg (1) and De Flora and Ramel
(2)]. However, in the majority of experi-
mental systems, protection has been
achieved by administering the chemo-
preventive agent prior to and/or concur-
rent with the exposure to the carcinogen.
Given this temporal relationship between
administration of anticarcinogen and car-
cinogen it seems likely that these agents act
principally by affecting the metabolism and
disposition ofcarcinogens, thereby altering
events critical to the initial interactions of
carcinogens with biomolecules. Using this
experimental approach, it has been possible
to document protection against a diverse
array ofchemical carcinogens acting at dif-
ferent target organ sites. Important classes of
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chemopreventive agents that modulate the
metabolic processing ofcarcinogens include
phenolic antioxidants, indoles, isothio-
cyanates, coumarins, flavones, allyl sulfides,
dithiocarbamates, and dithiolethiones.
A key component in understanding the
initial events of carcinogenesis was the
recognition that many chemical carcino-
gens are not chemically reactive per se, but
must undergo metabolic activation to form
electrophilic reactants (3). These reactive
species can interact with nucleophilic
groups in DNA to induce point mutations
and other genetic lesions, thus leading to
activation ofprotooncogenes and inactiva-
tion of tumor suppressor genes. The
importance of metabolic activation in car-
cinogenesis is highlighted by the fact that
target organ specificities and even species
susceptibilities can be determined through
the presence or absence of metabolic path-
ways. The metabolism of chemicals to
proximate carcinogens often involves an
initial two-electron oxidation to a hydroxy-
lated or epoxidated product and is typically
catalyzed by the cytochrome P450 system.
Collectively, the enzymes that catalyze the
formation of these reactive intermediates
are termed phase 1 enzymes. Cells also have
a variety of enzymatic and nonenzymatic
mechanisms that protect against damage by
electrophilic metabolites. A number of
enzymes transfer or conjugate various
endogenous substrates, such as glutathione,
glucuronide, and sulfate, to the products of
phase 1 metabolism. These phase 2 reac-
tions, which often add large polar mole-
cules to the primary metabolite, generally
limit further biotransformation by enhanc-
ing elimination, thereby leading to detoxi-
cation. Thus, the amount of ultimate
carcinogen available for interaction with its
target represents, in part, a balance between
competing activating and detoxifying reac-
tions. While this balance is under genetic
control, it is easily modulated by a variety
offactors including nutritional status, age,
hormones, and exposure to drugs or other
xenobiotics (4). In this setting, chemopre-
ventive agents can profoundly modulate the
constitutive metabolic balance between
activation and inactivation ofcarcinogens
through their actions on both phase 1 and
phase 2 enzymes. This review considers the
general role for inducers of electrophile
detoxication enzymes, principally the phase
2 enzymes, as anticarcinogens. To illustrate
the effectiveness of this strategy, a
discussion is also presented on the actions
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ofone class ofselective inducers ofphase 2
enzymes, the dithiolethiones, against
aflatoxin-induced hepatocarcinogenesis.
Mechanisms of Phase 2
Enzyme Induction
It has been known for several decades that
antioxidants such as butylated hydroxy-
toluene (BHT), butylated hydroxyanisole
(BHA), and ethoxyquin exert an anticar-
cinogenic effect when given simultaneously
(or prior to or both) with a carcinogen.
One ofthe earliest studies to indicate a role
for the induction ofphase 2 enzymes, par-
ticularly glutathione S-transferases (GSTs),
in the protective actions ofthese antioxi-
dants was that of Benson and co-workers
(5). They showed that liver cytosols from
BHA- or ethoxyquin-fed rats or mice
exhibited much higher GST activities than
controls and that cytosols prepared from
the livers of these rodents eliminated the
mutagenic activity in urine from mice
treated with benzo[a]pyrene. Subsequent
studies demonstrated that dietary adminis-
tration of antioxidants increased GST
activity in extrahepatic tissues such as lung,
stomach, small intestine, and kidney (6).
Substantial evidence now supports the view
that induction ofphase 2 enzymes is a crit-
ical and sufficient mechanism to engender
protection against the toxic and carcino-
genic actions ofreactive intermediates. The
evidence includes the following:
* Many chemopreventive agents are most
effective ifadministered prior to and/or
concurrent with carcinogens.
* Treatment with chemopreventive
agents profoundly alters carcinogen
metabolism.
* Induced phase 2 enzymes inactivate
electrophiles (ultimate carcinogens).
* chemoprevention is achieved against a
wide variety ofcarcinogens, suggesting
a lowspecificity mechanism.
* Enzyme induction and chemopreven-
tion are produced by the same com-
pounds (of many chemical classes),
occur at similar doses, and have similar
tissue specificities.
* Overexpression ofglutathione S-trans-
ferase by cDNA transfection protects
cells against carcinogen toxicity.
* Deficiencies in the levels ofexpression
of glutathione S-transferases may be
important determinants for susceptibil-
ity to cancer in humans.
* Monitoring enzyme induction has led
to the recognition or isolation ofnovel
chemopreventive agents.
Measurement of phase 2 enzyme
induction has led to the isolation oftwo
anticarcinogenic terpenoids, kahweol palmi-
tate and cafestrol palmitate, from green cof-
fee beans (7); isolation ofthe isothiocyanate
sulforaphane as the principal and very
potent phase 2 enzyme inducer from broc-
coli, and demonstration of its ability to
block dimethylbenzanthracene-induced
mammary tumorigenesis in rats (8,9); and
prediction ofthe anticarcinogenic effects of
1,2-dithiole-3-thiones, including oltipraz
(4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-
thione), which is now in clinical cancer
chemoprevention trials (10-12).
Initial studies on the possible molecular
mechanisms of induction of GSTs by
antioxidants were conducted by Pearson et
al. (13), who observed a 20-fold increase in
mRNA for the major GST in the livers of
mice several days after feeding 0.75%
BHA. Benson and colleagues subsequently
reported that significant increases in
mRNA levels could be observed as early as
24 hr after placing mice on the BHA-sup-
plemented diet (14). More recently,
Pearson et al. (15) have studied the mecha-
nisms of tissue-specific induction of
murine GST mRNAs by BHA. In these
studies, measurements of transcription
rates in isolated nuclei indicated that
increased mRNA levels were due to
increased rates oftranscription.
The molecular mechanisms regulating
the transcriptional activation of phase 2
enzymes by antioxidants and other induc-
ers have also been investigated. As origi-
nally proposed by Wattenberg (1), two
families ofphase 2 enzyme inducers exist,
based upon their ability to elevate phase 1
enzymatic profiles. Prochaska and Talalay
(16) have coined the terms bifunctional
and monofunctional inducers to describe
these compounds (Figure 1). Bifunctional
inducers (e.g., polycyclic hydrocarbons,
dioxins, azo dyes, flavones) can all be char-
acterized as large planar polycyclic aromat-
ics; they elevate phase 2 as well as selected
phase 1 enzymatic activities, such as aryl
hydrocarbon hydroxylase. These com-
pounds are potent ligands for the aryl
hydrocarbon (Ah) receptor, and the direct
participation ofthe Ah receptor in the acti-
vation ofAh hydroxylase gene transcrip-
tion has been demonstrated (17).
Moreover, since phase 2 enzyme inducibil-
ity by bifunctional inducers segregates in
mice that possess functional Ah receptors,
it had been presumed that these enzymes
were under the direct control of the Ah
receptor. Monofunctional inducers (phe-
nols, lactones, isothiocyanates, dithiocarba-
mates, and 1,2-dithiole-3-thiones) elevate
phase 2 enzymatic activities without signif-
icantly elevating phase 1 activities and do
not possess an obvious defining structural
Figure 1. Mechanisms of enzyme induction by monofunctional and bifunctional inducers in the rat. SH, sulfhydryl
group. Monofunctional inducers (e.g., oltipraz) transcriptionally activate phase genes such as GSTthrough the
antioxidant response element(ARE). Bifunctional inducers, e.g., polycyclic aromatic hydrocarbons (PAHs)transcrip-
tionally activate phase 1 and phase 2 genes directly through the xenobiotic response element (XRE). Some bifunc-
tional inducers can also undergo metabolism to intermediates that can mediate gene expression through the ARE.
Adapted from Prochaska and Talalay (16).
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characteristic. Since Ah-dependent phase 1
enzymes can activate procarcinogens to
their ultimate reactive forms, it is antic-
ipated that monofunctional inducers
would be more desirable candidates for
chemoprevention in man.
Early studies with alkyl ethers of
hydroquinones in vivo and diphenols in
vitro suggested that diphenols such as BHA
mediate their inductive effects via a chemi-
cal signal (18,19). It was also suggested that
bifunctional inducers induce phase 2
enzymes in part via a metabolic cascade,
wherein bifunctional inducers were metab-
olized by induced phase 1 enzymes to
species resembling monofunctional induc-
ers. Talalay et al. (20) have identified the
chemical signal present in some monofunc-
tional inducers: the presence or acquisition
of an electrophilic center. Many com-
pounds are Michael reaction acceptors (e.g.,
an olefin conjugated to an electron with-
drawing group) and potency is generally
paralleled by their efficiency as Michael
reaction acceptors. These generalizations
can account for the inducer activity of
many types ofchemopreventive agents and
have led to the identification ofother novel
classes of inducers, including acrylates,
fumarates, maleates, vinyl ketones, and
vinyl sulfones. Other classes ofmonofunc-
tional inducers, notably peroxides, vicinal
dimercaptans, heavy metals, arsenicals, and
dithiolethiones, exhibit a common capacity
for reaction with sulfhydryls by either
oxidoreduction or alkylation (21).
Several regulatory elements controlling
the expression and inducibility of the Ya
subunit ofmurine and rat GSTs by bifunc-
tional and monofunctional inducers have
been characterized (22,23). A 41-bp ele-
ment in the 5'-flanking region of the rat
GST Ya gene, termed the antioxidant
response element, and a homologous ele-
ment in 5'-region of the murine Ya gene,
designated the electrophile response ele-
ment, have been identified using a series of
5' deletion mutants fused to the chloram-
phenicol acetyl transferase gene and then
transfected into hepatoma cells. Prestera et
al. (21) have observed that many classes of
monofunctional inducers stimulate expres-
sion of a reporter gene through this 41-bp
electrophile-antioxidant enhancer element.
DNA footprinting and gel shift assays have
recently established specific interactions
between nuclear proteins and the elec-
trophile-antioxidant regulatory element;
however, the identity and exact role ofthese
proteins in the induction pathway remains
to be elucidated (24).
Assessment of Phase 2
Enzyme Induction
A number ofapproaches have been used to
assess phase 1 enzyme induction and inhi-
bition in humans, including measurement
of the pharmacokinetics of drug probes
and determination ofchanges in the dispo-
sition of endogenous substrates for the
cytochrome P450s ofinterest (25). These
approaches have been less useful for assess-
ing phase 2 induction, in part because the
rate-limiting step in their overall metabo-
lism is often the phase 1 enzyme compo-
nent. Nonetheless, pharmacologic and
dietary manipulations have been shown to
modify the phase 2 metabolism of
antipyrine, phenacetin, oxazepam, and
acetaminophen in humans (25,26).
Acetaminophen undergoes three conjuga-
tion reactions: glucuronidation, sulfation,
and glutathione addition. Measurement of
the fractional clearances to these metabo-
lites provides a simultaneous, three-way
measure ofdrug conjugation. Miners et al.
(27) observed that treatment with sulphin-
pyrazone or anticonvulsant drugs selec-
tively enhanced both glucuronidation and
mercapturic acid formation from aceta-
minophen. The mercapturic acid is derived
from the initial glutathione adduct.
Increases in urinary thioether excretion
(mercapturic acid and other products ofglu-
tathione conjugation) have been observed
following exposure ofhumans to cigarette
smoke, cancer chemotherapeutic drugs, and
industrial chemicals (28). However, the
quantitative relations between enzyme
induction and thioether excretion have not
been defined and the overall utility ofthis
approach remains to be established. Direct
measurements ofphase 2 enzyme activities
in blood cells and serum have also been used
to assess enzyme induction. In a recently
reported clinical study, small but significant
increases in plasma levels of a-class GST
were observed in volunteers consuming a
diet enriched in brussels sprouts (29).
Earlier studies in mice fed BHA indicated
that plasma levels of GST and quinone
reductase correlated with, but underesti-
mated, increased activity ofthese enzymes
in liver (30). Quinone reductase activity is
induced in human peripheral blood
lymphocytes by several classes of mono-
functional inducers, including dithiolethi-
ones (31); ongoing phase I clinical studies
with oltipraz indicate that some phase 2
enzyme mRNA levels and activities are
increased in peripheral lymphocytes ofindi-
viduals receiving the drug (12,32). An
intriguing approach for assessing the
pharmacodynamic action ofenzyme induc-
ers is highlighted by the recent work of
Sreerama et al. (33), who reported that lev-
els of GST and quinone reductase activity
were elevated in the saliva ofsubjects who
continually ingested large quantities ofcof-
fee or broccoli. Saliva may provide an easily
obtained medium for assessing the enzyme
inductive potential ofvarious diets and
drugs and for establishing the optimal dose
and schedule for chemopreventive interven-
tions. Nonetheless, despite the expanding
attention to the identification and utiliza-
tion of phase 2 enzyme inducers, much
developmental work is still required for the
accurate and facile assessment of their





rodents can be inhibited by a number of
antioxidants and is particularly suited for
mechanistic studies. A brief discussion of
the impact ofdithiolethiones on aflatoxin-
induced liver cancers will illustrate some of
the enzyme-inducing and anticarcinogenic
properties ofthis class ofchemopreventive
antioxidants. Dithiolethiones are five-mem-
bered cyclic sulfur-containing compounds
with radioprotective, chemopreventive,
chemotherapeutic, and antiviral activities
(11,12). For example, the drug oltipraz
shows significant antischistosomal activity
in experimental animals and in humans.
During studies on the mechanisms of
schistosomicidal activity of oltipraz,
Bueding et al. (10) noted that admin-
istration of this drug, as well as several
analogues, to mice resulted in marked ele-
vations ofthe activities ofphase 2 enzymes
in hepatic and extrahepatic tissues. These
findings led Bueding to predict that dithio-
lethiones such as oltipraz might be excel-
lent candidate compounds for cancer
chemoprevention studies (10). As recently
summarized elsewhere, oltipraz has subse-
quently proven to be an effective anticar-
cinogen in breast, colon, pancreas, lung,
forestomach, skin, bladder, and liver tumor
models (11). As a consequence, oltipraz
has undergone phase I clinical trial in the
United States (32,34).
Aflatoxin B1 (AFB1) is a potent hepato-
toxin and carcinogen in a wide variety of
animals and is linked epidemiologically
with a high incidence ofprimary hepato-
cellular carcinoma in humans (35).
Elimination ofaflatoxins from the human
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food supply throughout the world will be
extremely difficult and chemoprevention
offers an attractive alternative for popula-
tions at high risk for aflatoxin-induced dis-
eases. A number ofclassic chemopreventive
agents, notably BHA, BHT, and ethoxy-
quin, inhibit AFB1 carcinogenesis in rats
when fed simultaneously with the carcino-
gen (36,37). A search for protective agents
more amenable for use in man led to the
evaluation of oltipraz in this rat model..
After feeding male F344 rats either purified
diet or diet supplemented with 0.075%
oltipraz for 1 week, the animals received
AFB1 5 days a week for 2 weeks. One week
after cessation ofdosing, all animals were
restored to the control diet and maintained
until they became moribund or upon study
termination at 23 months. This 10-dose
exposure to AFB1 produced an 11% inci-
dence ofhepatocellular carcinomas in the
control animals, while an additional 9% of
these rats had hyperplastic nodules in their
livers (38). This incidence ofhepatic dis-
ease mirrors the lifetime incidence ofhepa-
tocellular carcinoma in humans in high-risk
areas ofChina, Southeast Asia, and Africa
(6,39). In the rat intervention study,
dietary oltipraz afforded complete protec-
tion against aflatoxin-induced hepatocellu-
lar carcinomas and hyperplastic nodules.
Further, no tumors were seen in either
group at extrahepatic sites, indicating that
oltipraz did not serve to merely shift target
organ specificity from the liver to other tis-
sues. No protection is observed ifoltipraz is
administered after exposure toAFB1 (40).
These protective actions ofoltipraz (as
well as the food antioxidants) are thought
to result primarily from an altered balance
between the activation and detoxication of
aflatoxin in the hepatocyte. In the case of
aflatoxin, alterations in the balance ofcom-
peting pathways ofthe ultimate carcinogen
aflatoxin-8,9-oxide directly modulate the
availability of the epoxide for binding to
DNA (Figure 2). Anticarcinogenic concen-
trations ofoltipraz in the diet markedly
induce activities ofGSTs in rat tissues to
facilitate conjugation ofglutathione to
aflatoxin-8,9-oxide, thereby enhancing its
elimination and coordinately diminishing
DNA adduct formation (41). Feeding
oltipraz for 1 week before exposure to AFB1
increases the initial rate ofbiliary elimina-
tion ofthe aflatoxin-glutathione conjugate
nearly 3-fold. Concordantly, feeding
oltipraz led to 3- to 4-fold increases in the
specific activity of rat liver GST and eleva-
tion in the levels ofsome a-, p-, and i-class
subunits. Quantitative high-performance
liquid chromatography analysis of GST
subunits showed that levels of subunits
Yb1, Yp, Yc2 and Ya2 were increased 5- to
10-fold. In comparison, levels ofsubunits
Yb2 and Yc1 were elevated 2- to 3-fold,
whereas subunit Ya1 was not induced (42).
Fortuitously, rat GST isozymes containing
the Ya2, Yb1, or Yc2 subunits exhibit sub-
stantial conjugation activity toward the
ultimate carcinogenic metabolite aflatoxin-
8,9-oxide (43). Molecular studies indicate
that initial increases in hepatic GST
mRNA and protein levels in response to
oltipraz were mediated through transcrip-
tional activation of GST genes (44) and
appear to be mediated by the antioxidant
response element (45). Induction ofGSTs
by oltipraz in primary cultures ofhuman
hepatocytes has also been observed (46). A
significant attribute of oltipraz is the
responsiveness of many tissues to its
enzyme inductive actions.
Oltipraz can also influence cytochrome
P450 activities. Western blotting indicates
small increases in several forms ofP450 fol-
lowing oltipraz treatment in vivo, especially
CYP1A2 and CYP3A2 (47). Perhaps more
notable, direct addition ofoltipraz to rat
microsomes inhibits AFB1 oxidation (48).
Inhibition of CYP1A2 and CYP3A4 by
oltipraz results in the reduction ofaflatoxin
metabolism to aflatoxin M1 and the 8,9-
oxide in primary cultures of human
hepatocytes (49). Urinary excretion ofafla-
toxin M1 also drops dramatically immedi-




aflatoxin-treated rats (50). Thus, both
inhibition ofcytochrome P450s and induc-
tion of electrophile detoxication enzymes
are likely to contribute to chemopreven-
tion by oltipraz, although kinetic argu-
ments suggest the latter could be more
important than the former.
A practical outcome ofa mechanism of
action involving enzyme induction arises
from the long biological half-life of the
enzyme inductive response. Although the
half-life ofoltipraz in rodents and man is
<6 hr, the inductive effects on some phase
2 enzymes persist for more than 1 week.
Thus, intermittent dosing schedules may
offer advantages (fewer side effects, greater
compliance) while maintaining efficacy
(enhanced carcinogen detoxication). With
this view in mind, the effect ofdose sched-
uling on inhibiting aflatoxin-induced
tumorigenesis has been recently evaluated.
Rats were treated with AFB1 daily for 28
consecutive days and received oltipraz daily,
twice weekly, once weekly, or not at all
throughout this period. Daily treatment
with oltipraz engendered >99% reduction
in hepatic tumor burden; remarkably, the
twice- and once-weekly regimens reduced
tumor burden by 97 and 95%, respectively
(42). While transient micromolar concen-
trations ofoltipraz appear to be required to
trigger the induction ofprotective enzymes,
sustained elevation ofplasma levels ofthe
drug were not necessary to achieve chemo-
prevention. By contrast, inhibition ofP450
























Figure2. Effect of oltipraz on the metabolism ofaflatoxin Bl.
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micromolar concentrations ofdrug, reflect-
ing the largely competitive nature of the
inhibition and the rapid turnover rates of
mammalian P450s.
A phase II clinical trial with oltipraz is
underway in Qidong, Jiangsu Province,
People's Republic ofChina, under the aus-
pices of the Shanghai Cancer Institute and
the Qidong Liver Cancer Institute. Qidong
is located at the mouth oftheYangtze River
and has a population ofmore than one mil-
lion. Hepatocellular carcinoma is the lead-
ing cause ofcancer death in Qidong with a
mortality rate of 55 per 100,000 per year
(39). Major risk factors for liver cancer in
this region are infection with hepatitis B
virus and exposure to aflatoxins. Approx-
imately 10% ofthe population ofQidong
is positive for hepatitis B surface antigen.
Aflatoxins are consistent contaminants of
the food supply; the prevalence ofresidents
testing positive for aflatoxin biomarkers
exceeds 90% (51). Using a nested
case-control study design, Qian et al. (52)
reported highly significant associations
between the presence ofurinary aflatoxins,
serum hepatitis B surface antigen positivity,
and risk of hepatocellular carcinoma.
Particularly striking was a marked synergis-
tic interaction between viral and chemical
risk factors. Collectively, these studies high-
light the importance of both large-scale
hepatitis B virus vaccination programs and
limitation ofexposure and toxicities ofafla-
toxins as important strategies to decrease
the incidence ofliver cancer.
The randomized, placebo-controlled
trial has examined the effects of daily
(125 mg) and weekly (500 mg) doses of
oltipraz on levels of two independent bio-
markers: aflatoxin-N7-guanine adducts
excreted into urine and aflatoxin-albumin
adducts in serum. These two biomarkers
have been extensively validated through
ecological and prospective epidemiological
studies (51-53). While these biomarkers
reflect exposures to aflatoxins, their pres-
ence also signals increased risk for liver
cancer. Levels of these biomarkers can be
markedly attenuated in rats by intervention
with oltipraz during periods ofaflatoxin
exposure (38,54). As a consequence, blood
and urine samples have been collected
throughout a 2-month intervention period
as well as during a 2-month postinterven-
tion follow-up period to fully determine
the dynamics ofpotential changes in phase
2 enzyme activities and biomarker levels.
With 80 participants in each of the treat-
ment arms, the clinical trial has the power
to determine small decreases in the levels of
the urinary and/or serum biomarkers (55).
The availability ofintermediate biomarkers
reflecting the modulation of biologically
effective doses of environmental carcino-
gens as study end points allows the design
and conduct ofefficient clinical trials. We
hope that results from such trials with
oltipraz will provide insights into the util-
ity ofphase 2 enzyme induction as a useful,
mechanism-based approach to achieve
large-scale reductions in the incidence of
hepatocellular carcinoma in populations at
high risk for unavoidable exposures to afla-
toxins. Further, such studies may serve as
templates for chemopreventive interven-
tions targeting individuals at high risk for
other environmentally induced diseases.
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